[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-lung-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100598855","phase-2-prophylactic-proton-pump-inhibition-for-esophageal-protection-in-lung-radiation-therapy-100598855",false,"NCT07076914","Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy","Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy: A Randomized Clinical Trial","PPI-PROTECT","Inclusion Criteria:\n\n* Age 18 years or older\n\n  * Willing to provide informed consent\n  * Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n  * Life expectancy of at least 3 months\n  * Primary lung malignancy of any stage (including NSCLC and small cell lung cancer). Histologic\u002Fpathologic diagnosis is preferred, but not required.\n  * Receiving a prescribed dose of at least 40 Gy in 15 fractions (or equivalent). Eligible fractionations include, but are not limited to, 60 Gy in 30 fractions, 55 Gy in 20 fractions, and 40-45 Gy in 15 fractions.\n  * On radiation planning, at least 5 cc of esophagus is receiving at least 95% of prescription dose\n\nExclusion Criteria:\n\n* • Serious medical comorbidities precluding radiotherapy\n\n  * Use of PPI within 3 months prior to enrollment\n  * Allergy to PPI\n  * Odynophagia (painful swallowing) prior to enrollment\n  * Pregnant or lactating women\n\nNote: previous radiation to the thorax is allowed, as long as the composite plan of current and prior radiation doses meet standard institutional dose constraints, in the opinion of the treating radiation oncologist.","ALL","18 Years",{"count":20,"type":21},58,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A randomized controlled trial to assess the impact of prophylactic proton pump inhibitor use to improve esophagitis in lung cancer patients undergoing radiation. Patients will be randomized into a standard of care arm or the prophylactic proton pump (daily) arm.",[27,28,29],"Primary Lung Cancer","Non Small Cell Lung Cancer","Small Cell Lung Cancer",[31,32],"proton pump inhibitor","lung cancer","NOT_YET_RECRUITING","2025-07-20",{"date":36,"type":37},"2025-07-22","ACTUAL",{"date":39,"type":21},"2025-10-02",{"date":41,"type":21},"2032-10-02",{"name":43,"class":44},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100575710","epidemiology-of-abdominal-aortic-aneurysm-with-concomitant-primary-lung-cancer-100575710","NCT06775821","Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer","Inclusion Criteria:\n\n* Patients diagnosed with primary lung cancer through clinical or pathological examination\n\nExclusion Criteria:\n\n* Patients diagnosed with primary lung cancer who refuse to undergo abdominal aortic imaging screening.","20 Years","90 Years",{"count":55,"type":21},2000,"1 Year","OBSERVATIONAL","Retrospective clinical case studies in recent years have shown that most cases of lung cancer and abdominal aortic aneurysm (AAA) are detected at the same time and that there is a wide variation in the prevalence of AAA in patients with primary lung cancer reported in the literature, with some papers suggesting as high as 11%, suggesting that there may be a relationship between the prevalence of the two diseases. However, its exact incidence and mechanism are unknown. Accurate prevention of AAA in patients with primary lung cancer requires more in-depth studies. To solve the above problems, a multi-center prospective epidemiological investigation and mechanism study on the association of AAA in primary lung cancer combined has become particularly urgent. The results of the study will be of great significance for the follow-up treatment and prognosis of lung cancer patients as well as the improvement of long-term survival rate of lung cancer patients, and will also provide scientific basis and clinical guidance for the screening and prevention of AAA in lung cancer patients.",[60,27,61],"Abdominal Aortic Aneurysm","Prevalence",[60,63,64,65],"primary lung cancer","epidemiological studies","prevalence","RECRUITING","2025-01-11",{"date":69,"type":37},"2025-01-15",{"date":71,"type":37},"2022-10-01",{"date":73,"type":21},"2025-04-30",{"name":75,"class":44},"First Affiliated Hospital of Kunming Medical University"]